Drug General Information (ID: DDIV9AXN21)
Drug Name			Nabumetone		Drug Info		Oxaliplatin		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Nsaids/Analgesics				Antineoplastics
Structure

Mechanism of Nabumetone-Oxaliplatin Interaction (Severity Level: Moderate)
Decreased renal excretion due to nephrotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Nabumetone				Oxaliplatin
Mechanism		Nephrotoxicity				Primarily eliminated by renal excretion
Key Mechanism Factor 1
		Factor Name		Nephrotoxicity
		Factor Description		Drug-induced nephrotoxicity is a common and potentially serious complication of medication use. The kidneys are the primary organ for drug excretion, and when they are damaged can lead to decreased drug excretion.
Mechanism Description		Decreased renal excretion of Oxaliplatin caused by Nabumetone mediated nephrotoxicity

Recommended Action
Management		Caution is advised if oxaliplatin is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides polypeptide, glycopeptide, and polymyxin antibiotics amphotericin B adefovir cidofovir tenofovir foscarnet cisplatin deferasirox gallium nitrate lithium mesalamine certain immunosuppressants intravenous bisphosphonates intravenous pentamidine high intravenous dosages of methotrexate high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). The potential for increased toxicity of oxaliplatin such as peripheral sensory neuropathies and neutropenia should be considered. Renal function should be closely monitored during therapy.

References
1	Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.